Research use only.  Educational reference. Not medical advice. Not for human consumption.
📈 Long-Acting GHRH Analog

CJC-1295 with DAC (5 mg Vial) Dosage Protocol

CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analog modified with a maleimide group that covalently binds serum albumin, extending half-life from minutes to ~6–8 days.

⚡ Quickstart Highlights

Vial size
5 mg
Reconstitution
2 mL BAC water → 2.50 mg/mL
1 U-100 unit =
25.0 mcg
Frequency
1–2× weekly

Dosing & Reconstitution Guide

Route: Subcutaneous  |  Frequency: 1–2× weekly  |  Half-life: ~6–8 days

Standard Approach (2 mL = 2.50 mg/mL)

Reconstituting with 2 mL bacteriostatic water produces a concentration of 2.50 mg/mL. Volume per dose changes with concentration; mg dose itself does not change between vial sizes.

Phase / ProtocolDoseU-100 UnitsVolumeDoses per vial
Weeks 1–2 (titration)300 mcg12 units0.12 mL16 doses
Weeks 3–4500 mcg20 units0.20 mL10 doses
Weeks 5–6750 mcg30 units0.30 mL6 doses
Weeks 7–12 (target)1 mg40 units0.40 mL5 doses

Reconstitution Steps

  1. Wipe the vial stopper and BAC water vial with alcohol; let dry.
  2. Draw 2 mL of bacteriostatic water into a sterile syringe.
  3. Inject slowly down the inside glass wall of the peptide vial. Do not aim at the powder.
  4. Gently swirl until fully dissolved. Do not shake.
  5. Label with reconstitution date. Refrigerate at 2–8°C; use within 28 days.

Supplies Needed

Estimates for an 8-week and 12-week cycle at 750 mcg per dose, 1–2× weekly (1 dose/week).

Item8-Week Cycle12-Week Cycle
CJC-1295 with DAC (5 mg) vials2 vials2 vials
Insulin syringes (U-100)812
Bacteriostatic water (10 mL)1 × 10 mL1 × 10 mL
Alcohol swabs1 × 100-pack2 × 100-pack

Protocol Overview

CJC-1295 with DAC is unique in the GHRH class for its 6–8 day half-life — the maleimide-DAC linker covalently binds albumin, sustaining GH/IGF-1 elevation continuously rather than producing pulses. This is both an advantage (1-2× weekly injection schedule) and a tradeoff (continuous elevation may blunt natural pulsatility long-term).

Most protocols run 8–12 weeks then a break, on the rationale that continuous receptor activation may downregulate the GHRH receptor population.

Dosing Protocol

Titration schedule (1–2× weekly):

Cycle structure: 8–12 weeks active, then 4-week break. The DAC-modified molecule's long half-life means cleared levels persist 2–3 weeks after the last dose.

Stacking: Often combined with a GHRP (ipamorelin or hexarelin) which provides pulsatile GH peaks atop CJC-1295's elevated baseline — the most-cited combination protocol.

Timing: Day-of-week is flexible because of the long half-life. Most users dose Sunday/Wednesday or Monday/Thursday for the twice-weekly schedule.

Storage Instructions

StateTemperatureDuration
Lyophilized−20°C (−4°F)Up to 24 months, dry & dark
Reconstituted2–8°C (35–46°F)Up to 28 days, protect from light

Important Notes

⚠ Research Use Only: CJC-1295 with DAC is investigational. Limited human clinical trial data.

How This Works

CJC-1295 is a synthetic GHRH analog with four amino acid substitutions (D-Ala2, Gln8, Ala15, Leu27) for stability against DPP-4. The DAC version adds a maleimide N-(2-aminoethyl)-2-maleimide group that covalently attaches to serum albumin via a free cysteine, extending half-life dramatically.

It binds pituitary GHRH receptors, raising baseline GH and IGF-1 levels for sustained periods. The continuous elevation differs from physiological pulsatile GH and is one reason combinations with GHRPs (ipamorelin) are popular — GHRPs provide pulsatile peaks atop CJC-1295's elevated baseline.

Potential Benefits & Side Effects

Potential Benefits

Side Effect Profile

Lifestyle Factors

Injection Technique

References

1
Teichman SL et al. 'Prolonged stimulation of GH and IGF-I by CJC-1295' — JCEM, 2006 View source ↗